30-hydroxygambogic acid increases the efficacy of cisplatin in an HPV+ head and neck cancer in vivo model

Abstract Background Head and neck squamous cell carcinoma (HNSCC) affects more than half a million people annually, and nearly 80% of oropharyngeal cancer cases are caused by human papillomavirus (HPV). Current treatments include chemo- and radiotherapy, though the effectiveness of these therapies i...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sonia N. Whang, Valeria Rodarte, Trevor Lohman, Josh Barforough, Lennox Chitsike, Gina N. Lucas, David Lee, Caleb Ruiz-Jimenez, Yan Chen Wongworawat, Rouba Ali-Fehmi, Marya Wahidi, Juli Unternaehrer, Valery Filippov, Penelope J. Duerksen-Hughes
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Series:	BMC Cancer
Subjects:	Human papillomavirus (HPV) Head and neck cancer Head and neck squamous cell carcinoma (HNSCC) 30-hydroxygambogic acid (GA-OH) HPV+ mouse xenograft Combination therapy
Online Access:	https://doi.org/10.1186/s12885-025-14638-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

30-hydroxygambogic acid increases the efficacy of cisplatin in an HPV+ head and neck cancer in vivo model

Similar Items